James Kasinger Sells 3,450 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 3,450 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $48.26, for a total transaction of $166,497.00. Following the completion of the transaction, the general counsel owned 91,240 shares of the company’s stock, valued at approximately $4,403,242.40. The trade was a 3.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $47.69 on Thursday. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48. The firm has a 50-day moving average of $53.60 and a 200 day moving average of $57.17. The stock has a market cap of $4.58 billion, a P/E ratio of -7.31 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The business had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. During the same quarter last year, the company posted ($1.01) EPS. CRISPR Therapeutics’s revenue for the quarter was down 97.8% compared to the same quarter last year. Research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and raised its price target to $110, signaling strong upside expectations tied to CRSP’s pipeline and future catalysts. Read More.
• Positive Sentiment: Large institutional interest noted (including a new GSK stake and increases by several asset managers), which supports long-term conviction in CRISPR’s platform and programs. Read More.
• Neutral Sentiment: CRISPR completed a sizeable $600M convertible notes offering (reported in recent coverage) that improves near-term liquidity for R&D and operations but could lead to dilution depending on conversion terms. Investors will weigh cash runway benefits against potential share dilution. Read More.
• Neutral Sentiment: Market/price commentary: several news pieces note CRSP is moving more sharply than the broader market today; that reflects the stock’s higher volatility and mixed short-term drivers rather than a single new development. Read More.
• Negative Sentiment: Clustered insider selling on March 16: CEO Samarth Kulkarni, the general counsel and another named insider all sold shares (transactions disclosed in SEC filings). Multiple insiders selling the same day can be read negatively by traders as distribution or reduced confidence from insiders, putting near-term downward pressure on the stock. Read More.
• Negative Sentiment: Operational/financial headwinds persist: recent quarterly results missed EPS and revenue expectations and revenue declined materially year-over-year, keeping profitability and near-term commercialization risk in focus. Analysts’ ratings remain mixed, so negative news can trigger outsized moves. Read More.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. Mcguire Capital Advisors Inc. purchased a new stake in CRISPR Therapeutics during the 4th quarter valued at $25,000. Ramirez Asset Management Inc. purchased a new position in shares of CRISPR Therapeutics in the fourth quarter worth $26,000. Rothschild Investment LLC raised its stake in shares of CRISPR Therapeutics by 836.7% in the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in shares of CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after purchasing an additional 382 shares in the last quarter. Finally, Thompson Investment Management Inc. purchased a new stake in shares of CRISPR Therapeutics during the third quarter valued at $33,000. 69.20% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CRSP shares. Chardan Capital raised their price objective on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research report on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. TD Cowen increased their target price on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research note on Friday, February 13th. Bank of America reduced their price target on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Finally, Evercore reaffirmed an “outperform” rating and issued a $74.00 price target on shares of CRISPR Therapeutics in a research report on Friday, February 13th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and an average price target of $64.53.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.